

## A new future for R&D?

Measuring the return from pharmaceutical innovation 2017


R&D returns continue to fall for the large cap biopharma original cohort



Cost to **bring an asset to market** has increased to record levels in 2017 for the large cap biopharma original cohort




Projected peak sales per asset increase by 18% in 2017 for the large cap biopharma original cohort




Fewer Phase III trials starting in the past year sees a decline in number of late-stage assets



Returns for the extension cohort of mid-tier biopharma companies increased in 2017



Extension cohort of mid-tier biopharma companies face 50% more costs, since 2013, to bring an asset to market



2017



## A digital remedy for R&D productivity





Deloitte Centre for Health Solutions